BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patients with disease progression on BTKis, but data on B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Lin, Victor S., Lew, Thomas E., Handunnetti, Sasanka M., Blombery, Piers, Nguyen, Tamia, Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Anderson, Mary Ann
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316215/
https://ncbi.nlm.nih.gov/pubmed/32244251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020004782
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars